GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DE) » Definitions » Net Income Including Noncontrolling Interests

Melodiol Global Health (ASX:ME1DE) Net Income Including Noncontrolling Interests : A$-52.45 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Melodiol Global Health's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2023 was A$-24.20 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was A$-52.45 Mil.


Melodiol Global Health Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Melodiol Global Health's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Net Income Including Noncontrolling Interests Chart

Melodiol Global Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -15.34 -30.78 -30.03 -32.78 -52.45

Melodiol Global Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.06 -7.09 -25.69 -28.25 -24.20

Melodiol Global Health Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-52.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Melodiol Global Health Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Melodiol Global Health (ASX:ME1DE) Business Description

Industry
Traded in Other Exchanges
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DE) Headlines

No Headlines